Surgical Debulking Modifies Notch Signaling and May Improve Vismodegib Effectiveness for Locally Advanced Basal Cell Carcinoma
-
Published:2024-09
Issue:5
Volume:4
Page:100288
-
ISSN:2667-0267
-
Container-title:JID Innovations
-
language:en
-
Short-container-title:JID Innovations
Author:
Maglakelidze NatellaORCID,
Gettle Samantha L.ORCID,
Longenecker Amy L.ORCID,
Vidimos Allison T.ORCID,
Billingsley Elizabeth M.ORCID,
Hobbs Ryan P.ORCID,
Lam CharleneORCID
Reference18 articles.
1. Advanced treatment for basal cell carcinomas;Atwood;Cold Spring Harb Perspect Med,2014
2. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma;Axelson;Clin Cancer Res,2013
3. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial;Basset-Séguin;Eur J Cancer,2017
4. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant vismodegib in locally advanced basal cell carcinoma;Bertrand;EClinicalMedicine,2021
5. A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition;Biehs;Nature,2018